Buprenorphine HCl

CAS 53152-21-9

Interested in hearing more about this API?

Buprenorphine Hydrochloride is the hydrochloride salt form of buprenorphine, a synthetic phenanthrene with narcotic analgesic activity. Buprenorphine hydrochloride is a partial agonist at the mu-opioid receptor and an antagonist at the kapa-opioid receptor in the central nervous system. However, under the conditions of recommended use it behaves as a classic mu-opioid agonist, mimicking the actions of endogenous peptides at CNS opioid receptors. The agonist action results in a raised pain threshold and increased tolerance to pain. However, it also causes sedation, physical dependence, and respiratory depressant effects and decreases heart rate and blood pressure.

About the API

Technology

Synthetic

Therapeutic category

Neurology-Psychiatry

Regulations
EU CEP
US DMF
Systematic Name

(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol;hydrochloride

Disclaimers:

This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources. For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.

 

Contact us

Step 1 of

    First name*
    Last name*
    Business email*
    Company*
    Job title*
    Country*
    I'm interested in*
    Segment of interest*
    Tell us more about your project
    Select product*
    Formulation
    Project type*
    Target market
    Quantity
    Comments
    Disclaimer: This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.
    By clicking submit, you are agreeing to our Privacy Policy